Apolipoprotein A-II: Evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis

Annals of Medicine

Volumn 44, Issue 4, 2012, Pages 313-324

  Chan, Dick C ^a   Ng, Theodore W K ^b   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

ApoA II; Cardiovascular disease; HDL transport; Metabolic syndrome

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A2; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH DENSITY LIPOPROTEIN RECEPTOR; LIPID TRANSFER PROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; DNA POLYMORPHISM; DYSLIPIDEMIA; FATTY ACID METABOLISM; GENE CONTROL; GENE MUTATION; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; TRANSGENIC ANIMAL;

APOLIPOPROTEIN A-II; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; TRIGLYCERIDES;

EID: 84860138988     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.573498     Document Type: Review

References (109)

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707-14. (Pubitemid 8110784)
2. Gordon DJ, Probstfi eld JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15. (Pubitemid 19043669)
3. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86:19L-22L.
4. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-10. (Pubitemid 47481452)
5. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. Curr Opin Lipidol. 2006;17:238-46. (Pubitemid 43786057)
6. Watts GF, Barrett PH, Chan DC. HDL metabolism in context: looking on the bright side. Curr Opin Lipidol. 2008;19:395-404.
7. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-32. (Pubitemid 40962099)
8. Kontush A, Chapman MJ. Functionally defective highdensity lipoprotein: a new therapeutic target at the crossroads of dyslipidaemia, infl ammation, and atherosclerosis. Pharmacol Rev. 2006;58:342-74. (Pubitemid 44394906)
9. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94:706-14. (Pubitemid 351744686)
10. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786-98. (Pubitemid 47263161)
11. Cheung MC, Albers JJ. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res. 1982;23:747-53. (Pubitemid 13227207)
12. Castellani LW, Lusis AJ. ApoA-II versus apoA-I: two for one is not always a good deal. Arterioscler Thromb Vasc Biol. 2001;21:1870-2. (Pubitemid 34219734)
13. Frank PG, Marcel YL. Apolipoprotein A-I: structurefunction relationships. J Lipid Res. 2000;41:853-72.
14. Curtiss LK, Valenta DT, Hime NJ, Rye KA. What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol. 2006;26:12-19. (Pubitemid 43732223)
15. Rye KA, Barter PJ. Formation and metabolism of prebetamigrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2004;24:421-8. (Pubitemid 38326133)
16. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem. 2008;54:788-800. (Pubitemid 351671595)
17. Miyazaki O, Kobayashi J, Fukamachi I, Miida T, Bujo H, Saito Y. A new sandwich enzyme immunoassay for measurement of plasma pre-β1-HDL levels. J Lipid Res. 2000;41:2083-8. (Pubitemid 32039004)
18. Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, Kockx M, et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol. 2006;26:534-40 .
19. Fidge NH. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res. 1999;40:187-201. (Pubitemid 29069792)
20. Kalopissis AD, Pastier D, Chambaz J. Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance. Curr Opin Lipidol. 2003;14:165-72. (Pubitemid 36521187)
21. Chambaz J, Cardot P, Pastier D, Zannis VI, Cladaras C. Promoter elements and factors required for hepatic transcription of the human ApoA-II gene. J Biol Chem. 1991;266:11676-85. (Pubitemid 21907002)
22. Brewer HB, Lux SE, Ronan R, John KM. Amino acid sequence of human apoLp-Gln-II (apoA-II), an apolipoprotein isolated from the high-density lipoprotein complex. Proc Natl Acad Sci USA. 1972;69:1304-8.
23. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res. 1992;33:141-66.
24. Li WH, Tanimura M, Luo CC, Datta S, Chan L. The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution. J Lipid Res. 1988;29:245-71.
25. Hussain MM, Zannis VI. Intracellular modifi cation of human apolipoprotein AII (apoAII) and sites of apoAII mRNA synthesis: comparison of apoAII with apoCII and apoCIII isoproteins. Biochemistry. 1990;29:209-17. (Pubitemid 20033727)
26. Ikewaki K, Zech LA, Brewer HB Jr, Rader DJ. ApoA-II kinetics in humans using endogenous labeling with stable isotopes: slower turnover of apoA-II compared with the exogenous radiotracer method. J Lipid Res. 1996;37: 399-407.
27. Velez-Carrasco W, Lichtenstein AH, Li Z, Dolnikowski GG, Lamon-Fava S, Welty FK, et al. Apolipoprotein A-I and a-II kinetic parameters as assessed by endogenous labeling with [2H3]leucine in middle-aged and elderly men and women. Arterioscler Thromb Vasc Biol. 2000; 20:801-6. (Pubitemid 30151696)
28. Gong EL, Stoltzfus LJ, Brion CM, Murugesh D, Rubin EM. Contrasting in vivo effects of murine and human apolipoprotein A-II. J Biol Chem. 1996;271:5984-7. (Pubitemid 26095398)
29. Ladias JA, Hadzopoulou-Cladaras M, Kardassis D, Cardot P, Cheng J, Zannis V, et al. Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3. J Biol Chem. 1992;267:15849-60.
30. Cardot P, Chambaz J, Kardassis D, Cladaras C, Zannis VI. Factors participating in the liver-specifi c expression of the human apolipoprotein A-II gene and their signifi cance for transcription. Biochemistry. 1993;32:9080-93. (Pubitemid 24186229)
31. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest. 1995; 96:741-50.
32. N Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Hevman RA, Staels B, et al. Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol Cell Biol. 1996;16:3350-60. (Pubitemid 26199854)
33. Pissios P, Kan HY, Nagaoka S, Zannis VI. SREBP-1 binds to multiple sites and transactivates the human apoA-II promoter in vitro: SREBP-1 mutants defective in DNA binding or transcriptional activation repress apoA-II promoter activity. Arterioscler Thromb Vasc Biol. 1999;19:1456-69. (Pubitemid 29263015)
34. Kan HY, Pissios P, Zannis VI, Chambaz J. DNA binding specifi city and transactivation properties of SREBP-2 bound to multiple sites on the human apoA-II promoter. Nucleic Acids Res. 1999;27:1104-17. (Pubitemid 29209515)
35. Hachem H, Raynal G, Hamza M, Canal P, Soula G. Automated immunoturbidimetric assay of serum apolipoprotein A-II using the Cobas-Bio centrifugal analyser: infl uence of hyperlipoproteinemia. Clin Biochem. 1985;18:332-7. (Pubitemid 16171476)
36. Porsch-Ozcurumez M, Westphal S, Luley C. Measurement of low apolipoprotein concentrations by optimized immunoturbidimetric applications. Clin Chem. 2001;47:594-7. (Pubitemid 32222481)
37. Rosseneu M, Vinaimont N, Musliner TA, Bernier D, Herbert PN, Belpaire F. Immunonephelometry of apolipoprotein A-II in plasma. Clin Chem. 1984;30:234-7. (Pubitemid 14190272)
38. Koren E, Puchois P, Alaupovic P, Fesmire J, Kandoussi A, Fruchart JC. Quantifi cation of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay. Clin Chem. 1987;33:38-43. (Pubitemid 17104089)
39. Lagocki PA, Scanu AM. In vitro modulation of the apolipoprotein composition of high density lipoprotein. Displacement of apolipoprotein A-I from high density lipoprotein by apolipoprotein A-II. J Bio Chem. 1980;255: 3701-6. (Pubitemid 10011833)
40. de Beer MC, Castellani LW, Cai L, Stromberg AJ, de Beer FC, van der Westhuyzen DR. ApoA-II modulates the association of HDL with class B scavenger receptors SR-BI and CD36. J Lipid Res. 2004;45:706-15. (Pubitemid 38405677)
41. Guyard-Dangremont V, Lagrost L, Gambert P. Comparative effects of purifi ed apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity. J Lipid Res. 1994;35:982-92. (Pubitemid 24181103)
42. Lagrost L, Persegol L, Lallemant C, Gambert P. Infl uence of apolipoprotein composition of high density lipoprotein particles on cholesteryl ester transfer protein activity. Particles containing various proportions of apolipoproteins AI and AII. J Biol Chem. 1994;269:3189-97.
43. Hime NJ, Barter PJ, Rye KA. The infl uence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacylglycerol. J Biol Chem. 1998;273:27191-8. (Pubitemid 28500428)
44. Boisfer E, Lambert G, Atger V, Tran NQ, Pastier D, Benetollo C, et al. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridaemia due to defective very low density lipoprotein hydrolysis. J Biol Chem. 1999;274:11564-72.
45. Jahn CE, Osborne JC, Schaefer EJ, Brewer HB. In vitro activation of the enzymic activity of hepatic lipase by apoAII. FEBS Lett. 1981;131:366-8. (Pubitemid 12231357)
46. Sankaranarayanan S, Oram JF, Asztalos BF, Vaughan AM, Lund-Katz S, Adorni MP, et al. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol effl ux. J Lipid Res. 2009;50:275-84.
47. Remaley AT, Stonik JA, Demosky SJ. Apolipoprotein specifi city for lipid effl ux by the human ABCA1 transporter. Biochem Biophys Res. Commun. 2001;280:818-23. (Pubitemid 32924503)
48. Fournier N, Cogny A, Atger V, Pastier D, Goudouneche D, Nicoletti A, et al. Opposite effects of plasma from human apolipoprotein A-II transgenic mice on cholesterol effl ux from J774 macrophages and Fu5AH hepatoma Cells. Arterioscler Thromb Vasc Biol. 2002;22:638-43. (Pubitemid 34408746)
49. Tailleux A, Bouly M, Luc G, Castro G, Caillaud JM, Hennuyer N, et al. Decreased susceptibility to diet-induced atherosclerosis in human apolipoprotein A-II transgenic mice. Arterioscler Thromb Vasc Biol. 2000;20:2453-8.
50. Castro G, Nihoul LP, Dengremont C, de Geitere C, Delfl y B, Tailleux A, et al. Cholesterol effl ux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry. 1997;36:2243-9. (Pubitemid 27104718)
51. Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY, Julve-Gil J, Shen J, Calvet-Márquez S, et al. Functional lecithin:cholesterol acyltransferase defi-ciency and high density lipoprotein defi ciency in transgenic mice overexpressing human apolipoprotein A-II. J Biol Chem. 1996;271:6720-8. (Pubitemid 26104103)
52. Julve J, Escolà-Gil JC, Ribas V, González-Sastre F, Ordóñez-Llanos J, Sánchez-Quesada JL, et al. Mechanisms of HDL defi ciency in mice overexpressing human apoA-II. J Lipid Res. 2002;43:1734-42. (Pubitemid 35168288)
53. Koike T, Kitajima S, Yu Y, Li Y, Nishijima K, Liu E, et al. Expression of human apoAII in transgenic rabbits leads to dyslipidaemia: a new model for combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2009;29:2047-53.
54. Hedrick CC, Castellani LW, Warden CH, Puppione DL, Lusis AJ. Infl uence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem. 1993;268:20676-82. (Pubitemid 23278985)
55. Weng W, Breslow J. Inaugural article: dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc Natl Acad Sci USA.1996;93:14788-94.
56. Deeb SS, Takata K, Peng RL, Kajiyama G, Albers JJ. A splice-junction mutation responsible for familial apolipoprotein A-II defi ciency. Am J Hum Genet. 1990;46:822-7.
57. Shelley CS, Sharpe CR, Baralle FE, Shoulders CC. Comparison of the human apolipoprotein genes. Apo AII presents a unique functional intron-exon junction. J Mol Biol. 1985;186:43-51. (Pubitemid 16226563)
58. Van 't Hooft FM, Ruotolo G, Boquist S, de Faire U, Eggertsen G, Hamsten A. Human evidence that the apolipoprotein A-II gene is implicated in visceral fat accumulation and metabolism of triglyceride-rich lipoproteins. Circulation. 2001;104:1223-8. (Pubitemid 32848109)
59. De Oliveirae Silva ER, Kong M, Han Z, Starr C, Kass EM, Hank Juo SH, et al. Metabolic and genetic determinants of HDL metabolism and hepatic lipase activity in normolipidemic females. J Lipid Res. 1999;40:1211-21. (Pubitemid 29328524)
60. Park SH, Kim JR, Park JE, Cho KH. A Caucasian male with very low blood cholesterol and low apoA-II without evidence of atherosclerosis. Eur J Clin Invest. 2007;37:249-56. (Pubitemid 46439409)
61. De Gracia R, Fern án dez EJ, Ri ñ ón C, Selgas R, Garcia-Bustos J. Hereditary renal amyloidosis associated with a novel mutation in the apolipoprotein AII gene. QJM. 2006;99:274.
62. Yazaki M, Liepnieks JJ, Barats MS, Cohen AH, Benson MD. Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. Kidney Int. 2001;64:11-16.
63. Pussinen PJ, Jauhiainen M, Ehnholm C. ApoA-II/apoA-I molar ratio in the HDL particle infl uences phospholipid transfer protein-mediated HDL interconversion. J Lipid Res. 1997;38:12-21. (Pubitemid 27097070)
64. Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidaemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:1225-36.
65. Escola-Gil JC, Julve J, Marzal-Casacuberta A, Ordonez-Llanos J, Gonzalez-Sastre F, Blanco-Vaca F. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. J Lipid Res. 2001; 42:241-8. (Pubitemid 32206836)
66. Hedrick CC, Castellani LW, Wong H, Lusis AJ. In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions. J Lipid Res. 2001;42:563-70. (Pubitemid 32366999)
67. Castellani LW, Nguyen CN, Charugundla S, Weinstein MM, Doan CX, Blaner WS, et al. Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance. J Biol Chem. 2008;283:11633-44.
68. Warden CH, Hedrick CC, Qiao JH, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 1993;261:469-72. (Pubitemid 23276555)
69. Ferns GA, Shelley CS, Stocks J, Rees A, Paul H, Baralle F, et al. A DNA polymorphism of the apoprotein AII gene in hypertriglyceridaemia. Hum Genet. 1986;74:302-6. (Pubitemid 17056554)
70. Saha N, Tong MC, Tay JS, Jeyaseelan K, Humphries SE. DNA polymorphisms of the apolipoprotein B gene in Chinese coronary artery disease patients. Clin Genet. 1992;42:164-70.
71. Vohl MC, Lamarche B, Bergeron J, Moorjani S, Prud'homme D, Nadeau A, et al. The MspI polymorphism of the apolipoprotein A-II gene as a modulator of the dyslipidemic state found in visceral obesity. Atherosclerosis. 1997;128: 183-90. (Pubitemid 27092153)
72. Delgado-Lista J, Perez-Jimenez F, Tanaka T, Perez-Martinez P, Jimenez-Gomez Y, Marin C, et al. An apolipoprotein A-II polymorphism (-265T/C, rs5082) regulates postprandial response to a saturated fat overload in healthy men. J Nutr. 2007;137:2024-8. (Pubitemid 47367260)
73. Corella D, Arnett DK, Tsai MY, Kabagambe EK, Peacock JM, Hixson JE, et al. The-256T
74. Warden CH, Daluiski A, Bu X, Purcell-Huynh DA, De Meester C, Shieh BH, et al. Evidence for linkage of the apolipoprotein A-II locus to plasma apolipoprotein A-II and free fatty acid levels in mice and humans. Proc Natl Acad Sci USA. 1993;90:10886-90. (Pubitemid 23347148)
75. Magill P, Rao SN, Miller NE, Nicoll A, Brunzell J, St Hilaire J, et al. Relationships between the metabolism of high-density and very-low-density lipoproteins in man: studies of apolipoprotein kinetics and adipose tissue lipoprotein lipase activity. Eur J Clin Invest. 1982;12:113-20. (Pubitemid 12156164)
76. Julve J, Escolà-Gil JC, Rotllan N, Fiévet C, Vallez E, de la Torre C, et al. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. Arterioscler Thromb Vasc Biol. 2010;30:232-8.
77. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23: 201-29. (Pubitemid 34299024)
78. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes. 2007;56:2328-38. (Pubitemid 47358240)
79. Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol. 2010;30:1642-8.
80. Castellani LW, Gargalovic P, Febbraio M, Charugundla S, Jien ML, Lusis AJ. Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II. J Lipid Res. 2004;45:2377-87. (Pubitemid 39602986)
81. Castellani LW, Goto AM, Lusis AJ. Studies with apolipoprotein A-II transgenic mice indicate a role for HDLs in adiposity and insulin resistance. Diabetes. 2001;50:643-51. (Pubitemid 32195231)
82. Escola-Gil JC, Blanco-Vaca F, Julve J. Overexpression of human apolipoprotein A-II in transgenic mice does not increase their susceptibility to insulin resistance and obesity. Diabetologia. 2002;45:600-1. (Pubitemid 34533843)
83. Julve J, Escola-Gil JC, Marzal C, Ordonez-Llanos J, Gonzalez-Sastre F, Blanco-Vaca F. Increased production of very-low-density lipoproteins in transgenic mice overexpressing human apolipoprotein A-II and fed with a high-fat diet. Biochim Biophys Acta. 2000;1488:233-44.
84. Hanson RL, Ehm MG, Pettitt DJ, Prochazka M, Thompson DB, Timberlake D, et al. An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians. Am J Hum Genet. 1998;63:1130-8. (Pubitemid 30418584)
85. Elbein SC, Hoffman MD, Teng K, Leppert MF, Hasstedt SJ. A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians. Diabetes. 1999;48:1175-82. (Pubitemid 29226368)
86. Das SK, Chu W, Zhang Z, Hasstedt SJ, Elbein SC. Calsquestrin 1 (CASQ1) gene polymorphisms under chromosome 1q21 linkage peak are associated with type 2 diabetes in northern European Caucasians. Diabetes. 2004; 53:3300-6. (Pubitemid 39564507)
87. Meigs JB, Panhuysen CIM, Myers RH, Wilson PWF, Cupples LA. A genome-wide scan for loci linked to plasma levels of glucose and HbA1c in a community-based sample of caucasian pedigrees: The Framingham Offspring Study. Diabetes. 2002;51:833-40. (Pubitemid 34760197)
88. Schultz JR, Rubin EM. The properties of HDL in genetically engineered mice. Curr Opin Lipidol. 1994;5:126-37. (Pubitemid 24116877)
89. Escolà-Gil JC, Marzal-Casacuberta A, Julve-Gil J, Ishida BY, Ordóñez-Llanos J, Chan L, et al. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specifi c interaction with diet. J Lipid Res. 1998;39:457-62. (Pubitemid 28100682)
90. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993;365:762-4. (Pubitemid 23339884)
91. Brousseau T, Dupuy-Gorce AM, Evans A, Arveiler D, Ruidavets JB, Haas B, et al. Signifi cant impact of the highly informative (CA)n repeat polymorphism of the APOA-II gene on the plasma APOA-II concentrations and HDL subfractions: The ECTIM study. Am J Med Genet. 2002;110:19-24.
92. O'Brien T, Nguyen TT, Hallaway BJ, Hodge D, Bailey K, Holmes D, et al. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler Thromb Vasc Biol. 1995;15:228-31.
93. Roselli DR, Lapolla A, Sartore G, Rossetti C, Zambon S, Minicuci N, et al. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nineyear follow-up study. Nutr Metab Cardiovasc Dis. 2003;13:46-51. (Pubitemid 38561086)
94. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Bertrand M, Koren E, et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis. 1987;68:35-40. (Pubitemid 17151103)
95. Syvanne M, Kahri J, Virtanen KS, Taskinen MR. HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with noninsulin-dependent diabetes mellitus. Circulation. 1995;92: 364-70.
96. Buring JE, O'Connor GT, Goldhaber SZ, Rosner B, Herbert PN, Blum CB, et al. Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation. 1992;85:22-9.
97. Genest JJ, Bard JM, Fruchart JC, Ordovas JM, Wilson PF, Schaefer EJ. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis. 1991;90:149-57.
98. Calvo C, Olmos A, Ulloa N, Bustos A, Toledo L, Duran D, et al. [Lipoprotein particles LpA-I, LpA-I: A-II and LpB in coronary artery disease]. Rev Med Chil. 2000;128:9-16. [In Spanish] .
99. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 1997;17:715-22. (Pubitemid 27169133)
100. Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, et al. Relationships of HDL cholesterol, apoA-I, and apoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofi brate. Arterioscler Thromb Vasc Biol. 2009;29:950-5.
101. Sweetnam PM, Bolton CH, Downs LG, Durrington PN, MacKness MI, Elwood PC, et al. Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest. 2000;30: 947-56.
102. Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, Stroes ESG, Otvos JD, Wareham NJ, et al. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation. 2007;116:2029-35. (Pubitemid 350023748)
103. Winkler K, Hoffmann MM, Seelhorst U, Wellnitz B, Boehm BO, Winkelmann BR, et al. Apolipo protein A-II is a negative risk indicator for cardiovascular and total mortality: Findings from the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem. 2008;54:1405-6.
104. Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb Vasc Biol. 1992;12:701-7.
105. Luc G, Bard JM, Ferrières J, Evans A, Amouyel P, Arveiler D, et al. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: The PRIME Study. Arterioscler Thromb Vasc Biol. 2002;22:1155-61. (Pubitemid 34764867)
106. Asztalos BF, Demissie S, Cupples LA, Collins D, Cox CE, Horvath KV, et al. LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial. Atherosclerosis. 2006;188:59-67. (Pubitemid 44142535)
107. Blanco-Vaca F, Escola-Gil JC, Martin-Campos JM, Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res. 2001;42:1727-39. (Pubitemid 33116704)
108. C han DC, Watts GF, Ooi EMM, Rye KA, Ji J, Johnson AG, et al. Regulatory effects of fenofi brate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome. Diabetes Care. 2009;32:2111-3.
109. Brousseau ME, Millar JS, Diffenderfer MR, Nartsupha C, Asztalos BF, Wolfe ML, et al. Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism. J Lipid Res. 2009;50:1456-62.